A 2-week course of rifaximin (Xifaxan, Salix Pharmaceuticals) relieved bloating and other symptoms of irritable bowel syndrome for more than 2 months after treatment ended, according to research published January 6 in the New England Journal of Medicine. Rifaximin is the first treatment that targets the underlying cause of IBS, rather than just treating the symptoms, researchers said.
A 2-week course of rifaximin (Xifaxan, Salix Pharmaceuticals) relieved bloating and other symptoms of irritable bowel syndrome (IBS) for more than 2 months after treatment ended, according to research published January 6 in the New England Journal of Medicine. Rifaximin is the first treatment that targets the underlying cause of IBS, rather than just treating the symptoms, researchers said.
Two identically designed, phase-3, double-blind, placebo-controlled trials involved 1,260 individuals diagnosed with IBS but no constipation. They took either 550 mg of rifaximin or a placebo 3 times daily for 2 weeks and were followed for an additional 10 weeks. In the 4 weeks after treatment, nearly 41% of those who received rifaximin in the 2 trials reported adequate relief of IBS symptoms, compared with about 32% of the placebo group. About 40% in the rifaximin group said they found relief from bloating, compared with about 30% in the placebo group for both trials.
“This research shows that antibiotics work for patients with IBS, suggesting the intestinal microbiota has a role in causing this condition,” said Yehuda Ringel, MD, a gastroenterologist and associate professor of medicine at the University of North Carolina and a co-author of the study. “The effect lasted for 10 weeks after discontinuation of the medication, suggesting we are changing something in the underlying abnormality.”
Raleigh, N.C.-based Salix Pharmaceuticals funded the research. FDA is reviewing the company’s supplemental New Drug Application for rifaximin 550-mg tablets for the proposed indication of the treatment of IBS without constipation. The drug currently is approved for treating traveler’s diarrhea and hepatic encephalopathy, a brain disorder caused by liver disease.
AstraZeneca, Daiichi Sankyo Submit New BLA for Datopotamab in Lung Cancer
November 12th 2024After feedback from the FDA, the companies have voluntarily withdrawn the previous biologics licensing application for datopotamab deruxtecan for patients with advanced or metastatic nonsquamous non-small cell lung cancer.
Read More
Skyrizi Overtakes Humira in U.S. Sales Numbers
November 8th 2024For the first time, Skyrizi has replaced Humira as AbbVie’s sales driver, largely due to companies encouraging “product hopping” to avoid competition, creating concerns for the sustainability of the burgeoning adalimumab biosimilar market.
Read More